William Adams is an accomplished and experienced patent attorney, and his primary focus is patent litigation in the biotechnology, pharmaceutical, and medical device fields. William has been involved in numerous disputes on behalf of life sciences and pharmaceutical companies, and is co-chair of the firm’s Life Sciences Litigation Group.
William has extensive experience in U.S. federal district courts regarding pharmaceutical patent litigation involving Abbreviated New Drug Applications under the Hatch-Waxman Act. Moreover, William has been involved in counseling clients under the Biologics Price Competition and Innovation Act (the “BPCIA”). William’s technical training (B.S. in Chemical Engineering & M.S. in Biotechnology), along with his previous experience working as a pharmaceutical development scientist at a leading drug delivery company allows him to quickly understand the technology at issue. William has had success on behalf of his clients in federal district courts, at the ITC, and at the USPTO.
Having spent time as in-house IP counsel, William truly understands the demands, perspectives, and budgets of his clients. That in-house experience has helped William ensure that each matter and case entrusted to him by his clients is handled efficiently and effectively.
Recognized by The Legal 500 "United States" for Patent Litigation (2023)
What Celgene Corp. v. Peter Means For Biosimilar Developers | Biosimilar Development, Biosimilar Development (September 2019)
Speeches & Seminars
“Navigating the Patent Landscape for Biosimilars in the United States” World Biosimilars Congress USA 2020, Festival of Biologics, San Diego, CA (March 4, 2020)
“What legal strategies can be adopted to address patent challenges with products with substantial patent portfolios: What can be done to tackle big patent portfolios?” World Biosimilars Congress, Festival of Biologics, Basel, Switzerland 2019 (October 16, 2019)
“Untangling the Inner Workings of IPRs for Biosimilars,” ACI 9th Annual Summit on Biosimilars (June 27, 2018)
“Navigating the Patent Landscape for Biosimilars” World Biosimilars Congress USA 2018 (May 23, 2018)